Philemon Papanastasiou
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.
Journal: Paediatric drugs
Published: July 30, 2025
Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 14, 2025
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
Journal: American journal of clinical dermatology
Published: April 03, 2023
Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomized controlled trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 08, 2022
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Journal: Paediatric drugs
Published: April 03, 2022
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Journal: Acta dermato-venereologica
Published: February 11, 2022
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 20, 2020
Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
Journal: Journal of drugs in dermatology : JDD
Published: October 15, 2016
Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 05, 2016
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Journal: Rheumatology (Oxford, England)
Published: February 01, 2013
Fracture risk and zoledronic acid therapy in men with osteoporosis.
Journal: The New England journal of medicine
Published: November 02, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026